Get the Stockscreener App
2.85
9.20%
0.24
After Hours:
2.80
-0.05
-1.75%
Newcelx Ltd stock is traded at $2.85, with a volume of 5,249.
It is up +9.20% in the last 24 hours and down -14.16% over the past month.
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
See More
Previous Close:
$2.61
Open:
$2.61
24h Volume:
5,249
Relative Volume:
1.15
Market Cap:
$16.46M
Revenue:
Net Income/Loss:
$-2.17M
P/E Ratio:
-0.1643
EPS:
-17.3434
Net Cash Flow:
$-4.82M
1W Performance:
-8.36%
1M Performance:
-14.16%
6M Performance:
+14.00%
1Y Performance:
+0.00%
1-Day Range:
$2.61
$2.90
1-Week Range:
$2.61
$3.2787
52-Week Range:
$1.8299
$7.64
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
2.85 | 16.46M | 0 | -2.17M | -4.82M | -17.34 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Newcelx Ltd Stock (NCEL) Latest News
Positive Signs As Multiple Insiders Buy NewcelX Stock - Simply Wall Street
NewcelX (Nasdaq: NCEL) outlines $25M share deal with Alpha - Stock Titan
NewcelX (NASDAQ: NCEL) warns on cash as diabetes trial plans advance - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com
NewcelX Ltd (NCEL) Slides 2.87% to $3.38, Approaches Key Support at $3.21Mean Reversion Trade - siam.in
NewcelX (NCEL) Latest: Moves 3.18% Down to $3.26 in the Latest Session; the Near-Term Reference Band Stretches From $3.10 to $3.42 in Latest TradingPut Dominated - vinanet.vn
NewcelX (NCEL) Latest: Moves 3.18% Down to $3.26 in the Latest Session; the Near-Term Reference Band Stretches From $3.10 to $3.42 in Latest TradingHot Stock Picks - dars.gov.et
NewcelX Ltd (NCEL) Shareholders to Sell 694,000 Shares Amid Unpr - GuruFocus
NewcelX Ltd (NCEL) Pulls Back 2.54% as Shares Test Near-Term Support at $3.10Wyckoff Upthrust - vinanet.vn
NewcelX Ltd (NCEL) Pulls Back 2.54% as Shares Test Near-Term Support at $3.10Bullish Sentiment - dars.gov.et
NewcelX Ltd (NCEL) Pulls Back 2.54% as Shares Test Near-Term Support at $3.10Composite Profile - dars.gov.et
NewcelX Ord Shs (NCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewcelX (NCEL) Slides 6.2% to $3.34, Testing Key Support Near $3.17Diagonal Spread Trade - vinanet.vn
NewcelX Lines Up $1.4 Million Private Placement to Advance Type 1 Diabetes Program - theglobeandmail.com
NewcelX Ltd. (NCEL) Rises 3.83% to $3.49, Testing Key Resistance at $3.66Death Cross - vinanet.vn
Press Release: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing - Moomoo
NewcelX Announces $1.4 Million Private Placement at 20% Premium to Market to Advance NCEL-101 for Type 1 Diabetes - Quiver Quantitative
NewcelX Prices $1.4 Million Premium Equity Financing to Advance Type 1 Diabetes Cell Therapy - TipRanks
NewcelX Ltd. (NCEL) Edges Higher as Stock Tests Key Resistance at $3.70Post-Earnings Moves - dars.gov.et
NewcelX Ltd. (NCEL) Edges Higher as Stock Tests Key Resistance at $3.70Retail Volume - vinanet.vn
NewcelX Ord Shs (NCEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewcelX Ord Shs (NCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NewcelX Ord Shs (NCEL) Income Statement - TradingKey
NewcelX Ord Shs (NCEL) Balance Sheet - TradingKey
NewcelX Ord Shs (NCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewcelX Ord Shs (NCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewcelX Ord Shs (NCEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewcelX Ord Shs (NCEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NCEL|NewcelX Ord Shs|Price:3.755|Chg%:-0.070 - TradingKey
NewcelX Ord Shs (NCEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NCEL|NewcelX Ord Shs|Price:3.755|Chg%:-0.070 - TradingKey
NewcelX Ord Shs (NCEL) Cash Flow - TradingKey
NCEL|NewcelX Ord Shs|Price:3.755|Chg%:-0.070 - TradingKey
NewcelX Ltd. Revenue Breakdown – NASDAQ:NCEL - TradingView
NewcelX (NCEL) Secures Patent for Innovative Technology - GuruFocus
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio - The Manila Times
NewcelX Ltd. (NCEL) Holds Near $3.98 Support Zone After Modest DeclineRip Sell Trade - dars.gov.et
NewcelX Ltd. (NCEL) Holds Near $3.98 Support Zone After Modest DeclineAAII Bearish - dars.gov.et
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com Nigeria
Laidlaw Initiates NewcelX(NCEL.US) With Buy Rating, Announces Target Price $23 - Moomoo
NCEL Initiated Coverage by Laidlaw & Co. -- Price Target Announced at $23 - GuruFocus
Laidlaw initiates NewcelX stock with buy rating on diabetes therapy - Investing.com
NLSP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com South Africa
NewcelX Strengthens Diabetes Push With Appointment of Leading Transplant Pioneer Camillo Ricordi - TipRanks
NewcelX appoints diabetes researcher Ricordi to advisory board - Investing.com
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board - The Manila Times
NewcelX appoints diabetes research pioneer Dr. Camillo Ricordi to boost Type 1 diabetes therapy development. - Pluang
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com Canada
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com UK
Newcelx Ltd Stock (NCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Newcelx Ltd Stock (NCEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Revel Michel | CSO and Director |
Apr 27 '26 |
Buy |
2.75 |
54,545 |
149,999 |
957,530 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):